Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study

DSF-family quorum sensing signal-mediated intraspecies, interspecies, and inter-kingdom communication

“…Chronic colonization and infection by P. aeruginosa occur in 80% of cystic fibrosis (CF) patients, who are often coinfected by B. cenocepacia, S. maltophilia, as well as the fungus Aspergillus sp. [42]. As described previously, these three bacteria each produce the DSF molecules, PDSF, BDSF, and XcDSF, respectively, that mediate, in order, category III, II, and I intraspecies communication (Figure 1).…”

An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples

“…Oral antifungal medication use in the adult CF population can be high and may in part explain declining Af prevalence during older age. Our previous UK registry study suggested that anti-fungal prescribing is increased in those with chronic Pa irrespective of their Af status, presumably based on clinical markers of disease severity [5] .…”

“…Aspergillus fumigatus (Af), is the commonest fungus in the cystic fibrosis (CF) airway [1] and is linked with worsened structural airways disease, lung function, exacerbation frequency and qualityof-life [2][3][4][5][6] . Azole treatment of Af-colonisation, resulting in sig-nificant Af airway biomass reduction, improved CT scores and exacerbation rates [7] .…”

Improving Outcomes for Patients With Sickle Cell Disease in the United States

“…10 The Cystic Fibrosis Foundation Patient Registry (CFFPR) has allowed for robust quality improvement, including care guidelines with recommended nutrition and antibiotics, as well as disease-modifying therapies for the pulmonary and gastrointestinal complications of the disease. 45,46 The target population for the CFFPR is everyone with cystic fibrosis in the US; however, the registry is estimated to account for only 81% to 84% of the population of individuals with cystic fibrosis. 10 The discrepancy is because of inherent exclusion of patients not seen at least annually by an accredited cystic fibrosis care center and patients who do not consent to data collection.…”

“…The cystic fibrosis registry, which has been in place since 1986, provides detailed demographic information individuals living with cystic fibrosis to patients, clinicians, and researchers . The Cystic Fibrosis Foundation Patient Registry (CFFPR) has allowed for robust quality improvement, including care guidelines with recommended nutrition and antibiotics, as well as disease- modifying therapies for the pulmonary and gastrointestinal complications of the disease . The target population for the CFFPR is everyone with cystic fibrosis in the US; however, the registry is estimated to account for only 81% to 84% of the population of individuals with cystic fibrosis .…”